Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

DBV Technologies Q3 2026 Results: Net Loss of $64.5M, Loss Widens

As of September 30, 2026, DBV Technologies reported total assets of $215.4 million, down from $233.7 million at the end of 2025, primarily driven by a decrease in cash and cash equivalents to $165.7 million. The company is focused on regulatory submissions for its VIASKIN Peanut patch, including a BLA for children aged 4-7 and toddlers aged 1-3.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.62.8
Profit before tax-64.2-33.2
Net income-64.5-33.2
EPS (diluted, $ a share)$-0.14$-0.24

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-42.9%
Source

10-Q filed with the SEC, NASDAQ: DBVT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

DBV Technologies S.A.: key numbers

Share price
$10.27Close, Nov 16
Market cap
$3.23B
Shares outstanding
314.39MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from DBV Technologies S.A.

All →
5:25 PM ET 8-K
Financial Results

DBV Technologies Financial Results

DBV Technologies reported Q3 2026 financial results, highlighting the submission of its Biologics License Application (BLA) to the FDA for the Viaskin Peanut Patch in children aged 4-7 years. The company reported a cash position of $165.7 million, which is expected to fund operations into the third quarter of 2027 as it prepares for potential commercial launch.

Term
Q3 2026

“The third quarter marked a defining step in DBV’s evolution from a clinical-stage company into a commercial organization. With our BLA now submitted for children aged 4 through 7 years, and our planned BLA in toddlers aged 1 through 3 years, we are concentrating our efforts on the areas that will advance the company most meaningfully.”

Daniel Tassé, Chief Executive Officer of DBV Technologies

“We are grateful for the productive, ongoing dialogue with the FDA about both BLAs. As the regulatory dialogue progresses, we have every function across the company aligned on supporting a complete and efficient review of both dossiers, advancing manufacturing readiness alongside our contract manufacturing partner, and preparing to execute our launch plans with discipline.”

Daniel Tassé, Chief Executive Officer of DBV Technologies
6:04 AM ET 8-K
Other 8-K Filing

DBV Technologies Other 8-K Filing

DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for its VIASKIN Peanut Patch for children aged 4-7 years. The submission is based on positive Phase 3 VITESSE trial results and marks the company's transition toward a commercial-stage organization. The company has requested Priority Review for the application.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.